1-(Bromomethyl)-4-fluorocyclohexane | 1784609-74-0

• 分子结构分类: 有机化合物 - 有机卤素化合物 - 卤代烷
• 英文名称: 1-(Bromomethyl)-4-fluorocyclohexane
• CAS: 1784609-74-0
• 化学式: C₇H₁₂BrF
• 分子量: 195.07
• InChiKey: AEDCPJATJOCVQP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  9
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  0
• 氢给体数：
  0
• 氢受体数：
  1

文献信息

• HETEROCYCLIC P2X7 ANTAGONISTS
  申请人：AXXAM S.p.A.

  公开号：EP3619200A1

  公开（公告）日：2020-03-11
• US7157469B2
  申请人：——

  公开号：US7157469B2

  公开（公告）日：2007-01-02
• [EN] NOVEL COMPOUNDS USEFUL AS CC CHEMOKINE RECEPTOR LIGANDS<br/>[FR] NOUVEAUX COMPOSÉS UTILES COMME LIGANDS DE RÉCEPTEUR DE CHÉMOKINE CC
  申请人：FOREST LAB HOLDINGS LTD

  公开号：WO2010077915A1

  公开（公告）日：2010-07-08

  The present invention relates to novel morpholine, oxazapane and piperidine derivatives that act as ligands for CC chemokine receptors, such as CCRl. The invention also relates to methods of preparing the compounds, compositions containing the compounds, and to methods of treatment using the compounds.
• [EN] HETEROCYCLIC P2X7 ANTAGONISTS<br/>[FR] ANTAGONISTES HÉTÉROCYCLIQUES DE P2X7
  申请人：AXXAM SPA

  公开号：WO2018202694A1

  公开（公告）日：2018-11-08

  The present invention refers to compounds of the following formula (I) or a pharmaceutically acceptable salt thereof, to pharmaceutical compositions containing them and to a process for the preparation of said compounds: Formula (I), wherein: R1 is independently selected from hydrogen atom, amine group, monocyclic or bicyclic aliphatic, aromatic, heteroaliphatic or heteroaromatic ring, optionally substituted by one or more substituents selected from C1-C4 alkyl optionally substituted by one or more halogen atom(s), halogen, C1-C4 alkoxy or phenyl group, optionally substituted by C1-C4 alkyl; R2 is independently selected from monocyclic or bicylic aliphatic, heteroaliphatic, aromatic or heteroaromatic ring, C1-C6 alkyl, alkenyl or alkynyl chain, optionally substituted by one or more substituents selected from C1-C4 alkyl optionally substituted by one or more halogen atom(s), halogen, C1-C4 alkoxy, cyano, C1-C4 alkylthio, SO-C1-C4 alkyl, SO2-C1-C4 alkyl, N(C1-C4 alkyl)2; n is 1 or 2; preferably n is 1; m is 0, 1 or 2; preferably m is 0; R3 and R4 can be, independently, -H, -F, C1-C4 alkyl, -OH, -OC1-C4 alkyl; preferably they are both -H; X is O or S; R5 is -H or -CH3 optionally substituted by one or more fluorine atoms; preferably R5 is hydrogen. The compounds of the invention can be used in the treatment of conditions or diseases mediated by P2X7 receptor.